v3.25.4
Shareholders' Equity - Share capital (Details)
1 Months Ended 12 Months Ended
Dec. 31, 2022
EUR (€)
shares
Dec. 31, 2022
USD ($)
shares
Sep. 30, 2021
shares
Dec. 31, 2025
EUR (€)
€ / shares
shares
Dec. 31, 2024
EUR (€)
shares
Dec. 31, 2023
shares
Shareholders Equity            
Authorized share capital | €       € 13,600,000    
Par value per share | € / shares       € 0.04    
Shares issued in the period | €         € 71,633,000  
Eli Lilly and Company            
Shareholders Equity            
Issue of ordinary shares (in shares) 9,381,586 9,381,586 3,989,976      
Gross proceeds from issuance of shares € 14,122,000 $ 15,000,000        
Transaction cost | € € 0          
Ordinary            
Shareholders Equity            
Balance at beginning of period (in shares)       107,710,916 84,248,384 84,246,967
Issued for cash         23,463,610  
Exercise of share options / vesting of RSUs       148,537 394,481 537,513
Treasury shares issued (transferred)       (148,537) (395,559) (536,096)
Balance at end of period (in shares) 84,246,967 84,246,967   107,710,916 107,710,916 84,248,384
Number of shares authorised       170,000,000    
Number of shares issued and fully paid       105,361,064    
Treasury shares       2,349,852 2,498,389  
Ordinary | Previously stated            
Shareholders Equity            
Exercise of share options / vesting of RSUs         (395,559)  
Treasury shares issued (transferred)         394,481  
Preferred            
Shareholders Equity            
Number of shares authorised       170,000,000